Akhriska Oo Qofku Marka Uu Weynaado Ku Adkaadaa Waa Calaamad Muujinaysa Xanuun

Published on Oct 08 2017 // Googooska Geeska

Berlin (Geeska)- Jimciyadda caafimaadka indhaha ee dalka Jarmalka ayaa sheegtay in qofka oo akhrisku uu ku adkaado, sida akhriska wargeysyada, majalladaha, buuggaagta, ama xitaa akhriska qoraalka saacadda gacantu ay tahay xaalad u baahan in uu dhaqso u arko dhakhtar indhaha ah, waayo waxa ay noqon kartaa calaamad tilmaamaysa in qofka ay ku dhacday xaaladda Afingiriisiga lagu yidhaahdo, ‘Macular degeneration’ oo ah aragdarraan inta badan da’da ku timaadda.

Aragdarraantan Afingiriisiga lagu yidhaahdo Macular degeneration oo sida oo kalana lagu magacaabo ‘age-related macular degeneration’ loona soo gaabsado xarfaha ‘AMD ama ARMD’ waa dhaawac soo gaadha shabakadda iyo dareenwadeyaasha aragga kadibna sababa aragga oo daciifa ama wada luma. Xaaladdan oo inta badan ku timaadda da’da 50 jirka iyo ka weyn waxa uu ku yimaaddaa qoyaan badan ama ingag badan oo indhaha ku yimaadda, waxa aana qofka ku adaada wax akhriska, ama xitaa garahada wejiyada dadka, iyada oo haddana uu si fiican wax u arkayo, hawlmaalmeedkiisana u wato si aanu ka dareemayn arag darraan.

Calaamadaha kale ee uu qofku ku garan karo xanuunkan aragga dilaya waxaa ka mid ah qofka oo araggiisa khalkhal galo, sida in shayga uu arkayo oo toosan uu u arko in uu xoodan yahay.

Jimciyadda warbixintan soo saartay oo sii faahfaahinaysa ayaa sheegtay in dhaawacani uu soo gaadhayo shabakadda aragga, gaar ahaan qaybteeda masuulka ka ah saafi noqoshada aragga.

Waxa ay dhakhaatiirtu ku talinayaan in qofka xaaladdan isku arkaa uu sida ugu dhaqsaha badan ula xidhiidho dhakhtarka indhaha, maadaama oo xaaladdani ay khatar ku tahay caafimaadka araggiisa. Waxa aanay hoosta ka xariiqeen in xanuunkan noociisa qoyaanka indhaha keenaa uu yahay mid la daweyn karo ama ugu yaraan dib loo riixi karo dhaawaca uu indhaha u geysanayo, halka noociisa ingaggan aanay dhakhaatiirtu illaa hadda waxba ka qaban karin.

 

Leave a comment

Subscribe to our RSS Feed! Follow us on Facebook! Follow us on Twitter! Visit our LinkedIn Profile!